Medtronic MDT underwent analysis by 15 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 0 | 4 | 11 | 0 | 0 |
| Last 30D | 0 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 2 | 3 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 2 | 8 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $94.73, a high estimate of $106.00, and a low estimate of $85.00. Witnessing a positive shift, the current average has risen by 3.64% from the previous average price target of $91.40.
Exploring Analyst Ratings: An In-Depth Overview
The standing of Medtronic among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Richard Newitter | Truist Securities | Raises | Hold | $93.00 | $90.00 |
| Shagun Singh | RBC Capital | Raises | Outperform | $105.00 | $98.00 |
| Shagun Singh | RBC Capital | Raises | Sector Perform | $98.00 | $92.00 |
| Vijay Kumar | Evercore ISI Group | Raises | Outperform | $104.00 | $100.00 |
| Joanne Wuensch | Citigroup | Raises | Neutral | $92.00 | $85.00 |
| Richard Newitter | Truist Securities | Raises | Hold | $90.00 | $85.00 |
| Matt Miksic | Barclays | Raises | Overweight | $105.00 | $104.00 |
| Steven Lichtman | Oppenheimer | Raises | Perform | $94.00 | $92.00 |
| Matt O'Brien | Piper Sandler | Raises | Neutral | $90.00 | $85.00 |
| Shagun Singh | RBC Capital | Maintains | Sector Perform | $92.00 | $92.00 |
| Larry Biegelsen | Wells Fargo | Raises | Overweight | $106.00 | $105.00 |
| David Rescott | Baird | Raises | Neutral | $90.00 | $82.00 |
| Rick Wise | Stifel | Raises | Hold | $87.00 | $85.00 |
| Danielle Antalffy | UBS | Raises | Neutral | $90.00 | $76.00 |
| Rick Wise | Stifel | Lowers | Hold | $85.00 | $100.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Medtronic. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Medtronic compared to the broader market.
- Price Targets: Analysts predict movements in price targets, offering estimates for Medtronic's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Medtronic's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on Medtronic analyst ratings.
Unveiling the Story Behind Medtronic
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for roughly 50% of the company's total sales.
A Deep Dive into Medtronic's Financials
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Positive Revenue Trend: Examining Medtronic's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 2.77% as of 31 July, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Medtronic's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 13.16%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Medtronic's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 2.12%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Medtronic's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 1.16%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Medtronic's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.58.
Analyst Ratings: Simplified
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
